## Fracture Prevention on Admission

This forms provides guidance for RACFs on fracture prevention considerations for all new residents on admission.

## **Resident Name**

## HISTORY **INITIALS:** Prior fracture: Vertebral\_\_\_\_\_ Hip □ More than one prior fracture (\*excluding hands, feet, ankles) □ Recently used systemic glucocorticoids and have had one prior fracture (\*excluding hands, feet, ankles) D Previously identified as high risk for fractures and has received osteoporosis treatments (prior to admission) □ Dementia □ Resident is at risk of falling Dedication review (Beer's criteria or STOPP/START criteria - psychotropics, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), proton pump inhibitors (PPIs) - by Pharmacist, GP, Medical Specialist (eg. Geriatrician) **DIAGNOSTICS & INVESTIGATIONS** [Undertaken as **INITIALS:** required/where possible] □ Chest X-Ray - screen for vertebral fractures □ Thoracic + Lumbar Spine X-Ray (lateral) - rule out vertebral fracture CBC, Calcium, Creatinine, Albumin, Alkaline Phosphatase, TSH □ Serum protein electrophoresis (for residents with vertebral fractures) □ 25-hydroxy-vitamin D □ Bone densitometry **OSTEOPOROSIS MEDICATIONS INITIALS:** Calcium supplementation up to 500 - 600mg daily if resident cannot □ Calcium mg once daily consume 1000 - 1300mg of calcium through diet □ Vitamin D3 UNITS oral once daily Alendronate, Risedronate and Zoledronic Acid are not recommended (1000-2000 UNITS for mild deficiency) for older individuals with severe renal insufficiency \*(CrCl <30ml/min) □ Alendronate 70mg once weekly Alendronate and Risedronate are not to be crushed, and are to be provided to elderly who have an empty stomach and can remain upright for 30 mins Denosumab (Prolia®) 60mg subcut every 6 months after administration. (Note: Risedronate DR can be taken with food or after □ Risedronate (Actonel®) 35mg oral once weekly meals, but the individual has to remain upright for at least 30 mins after) Denosumab and Zoledronic Acid medications may be options for older □ Risedronate DR (Actonel® DR) 35mg oral once weekly individuals who have difficulty taking oral medications due to dysphagia, an inability to sit up for 30 mins, cognitive impairment or intolerance □ Risedronate (Actonel®) 150mg oral once monthly If using Denosumab, monitor calcium levels due to higher risk of □ Teriparatide (Forteo®) 20mcg subcut daily hypocalcemia Romosozumab is for severe osteoporosis. It's contraindicated in people □ Zoledronic Acid (Aclasta®) 5mg IV once per year with hypocalcemia, so pre-existing hypocalcemia must be corrected prior □ Romosozumab (Evenity) two 105mg subcut injections, to initiating therapy with romosozumab. monthly for 12 months life time use DIETARY **INITIALS:** Dietician consultation for calcium enriched diet **OTHER INTERVENTIONS FOR FALL & FRACTURE INITIALS:** PREVENTION Balance, strength and functional training exercises - if at high risk of fractures. Consider other elements of a multifactorial intervention to prevent falls and fractures: Hip protectors Assessment of environmental hazards \_Minimization of physical or chemical restraints (no restraint if at all possible) Safe mobility devices \_Safe transferring devices and techniques □ Occupational therapy consultation □ Physiotherapy consultation Date: RN/EN Name (print): Verbal Order Nurse Signature: **RN/EN Signature:** Time:

Adapted from Papaioannou A, et al. CMAJ 2015;187(15), with permission

Osteoporosis Australia, Statement on Calcium and Vitamin D for Bone Health in Australian Adult Populations Reviewed December 2017. [Accessed 29 March 2021] available at <a href="https://healthybonesaustralia.org.au/wp-content/uploads/2020/11/Calcium-and-Vitamin-D-Position-Statement-December-2017.pdf">https://healthybonesaustralia.org.au/wp-content/uploads/2020/11/Calcium-and-Vitamin-D-Position-Statement-December-2017.pdf</a>